Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Treatment of nontoxic, nonobstructive goiter

Douglas S Ross, MD
Section Editor
David S Cooper, MD
Deputy Editor
Jean E Mulder, MD


Goiter refers to abnormal growth of the thyroid gland. Adults may have goiters that are diffuse or nodular, and the goiters may be associated with normal, decreased, or increased thyroid hormone production. The management of goiter depends upon the cause. This topic primarily focuses on the management of nontoxic, nonobstructive diffuse or multinodular goiter. The treatment of obstructive or substernal goiter, toxic multinodular goiter, Graves’ disease, thyroiditis, and goiter due to iodine deficiency are reviewed separately:

(See "Treatment of obstructive or substernal goiter".)

(See "Treatment of toxic adenoma and toxic multinodular goiter".)

(See "Graves' hyperthyroidism in nonpregnant adults: Overview of treatment".)

(See "Subacute thyroiditis".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Sep 11, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Bonnema SJ, Bennedbaek FN, Ladenson PW, Hegedüs L. Management of the nontoxic multinodular goiter: a North American survey. J Clin Endocrinol Metab 2002; 87:112.
  2. Bonnema SJ, Bennedbaek FN, Wiersinga WM, Hegedüs L. Management of the nontoxic multinodular goitre: a European questionnaire study. Clin Endocrinol (Oxf) 2000; 53:5.
  3. Chen AY, Bernet VJ, Carty SE, et al. American Thyroid Association statement on optimal surgical management of goiter. Thyroid 2014; 24:181.
  4. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995; 43:55.
  5. Hegedüs L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev 2003; 24:102.
  6. Wesche MF, Tiel-V Buul MM, Lips P, et al. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J Clin Endocrinol Metab 2001; 86:998.
  7. Cramon P, Bonnema SJ, Bjorner JB, et al. Quality of life in patients with benign nontoxic goiter: impact of disease and treatment response, and comparison with the general population. Thyroid 2015; 25:284.
  8. Nielsen VE, Bonnema SJ, Hegedüs L. Transient goiter enlargement after administration of 0.3 mg of recombinant human thyrotropin in patients with benign nontoxic nodular goiter: a randomized, double-blind, crossover trial. J Clin Endocrinol Metab 2006; 91:1317.
  9. Kay TW, d'Emden MC, Andrews JT, Martin FI. Treatment of non-toxic multinodular goiter with radioactive iodine. Am J Med 1988; 84:19.
  10. Hegedüs L, Hansen BM, Knudsen N, Hansen JM. Reduction of size of thyroid with radioactive iodine in multinodular non-toxic goitre. BMJ 1988; 297:661.
  11. Verelst J, Bonnyns M, Glinoer D. Radioiodine therapy in voluminous multinodular non-toxic goitre. Acta Endocrinol (Copenh) 1990; 122:417.
  12. Nygaard B, Hegedüs L, Gervil M, et al. Radioiodine treatment of multinodular non-toxic goitre. BMJ 1993; 307:828.
  13. Nygaard B, Faber J, Hegedüs L. Acute changes in thyroid volume and function following 131I therapy of multinodular goitre. Clin Endocrinol (Oxf) 1994; 41:715.
  14. Wesche MF, Tiel-v-Buul MM, Smits NJ, Wiersinga WM. Reduction in goiter size by 131I therapy in patients with non-toxic multinodular goiter. Eur J Endocrinol 1995; 132:86.
  15. Huysmans DA, Hermus AR, Corstens FH, et al. Large, compressive goiters treated with radioiodine. Ann Intern Med 1994; 121:757.
  16. LeMoll, R, Wesche, MF, Tiel-van-Buul, MM, et al. Determinants of longterm outcome of radioiodine in sporadic non-toxic goiter. Clin Endocrinol 1999; 50:783.
  17. Bonnema SJ, Bertelsen H, Mortensen J, et al. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab 1999; 84:3636.
  18. Villadsen MJ, Sørensen CH, Godballe C, Nygaard B. Need for thyroidectomy in patients treated with radioactive iodide for benign thyroid disease. Dan Med Bull 2011; 58:A4343.
  19. Hegedüs L, Bennedbaek FN. Radioiodine for non-toxic diffuse goitre. Lancet 1997; 350:409.
  20. Nygaard B, Farber J, Veje A, Hansen JE. Thyroid volume and function after 131I treatment of diffuse non-toxic goitre. Clin Endocrinol (Oxf) 1997; 46:493.
  21. Howarth DM, Epstein MT, Thomas PA, et al. Outpatient management of patients with large multinodular goitres treated with fractionated radioiodine. Eur J Nucl Med 1997; 24:1465.
  22. Nygaard B, Hegedüs L, Ulriksen P, et al. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med 1999; 159:1364.
  23. Huysmans AK, Hermus RM, Edelbroek MA, et al. Autoimmune hyperthyroidism occurring late after radioiodine treatment for volume reduction of large multinodular goiters. Thyroid 1997; 7:535.
  24. Nygaard B, Knudsen JH, Hegedüs L, et al. Thyrotropin receptor antibodies and Graves' disease, a side-effect of 131I treatment in patients with nontoxic goiter. J Clin Endocrinol Metab 1997; 82:2926.
  25. Schmidt M, Gorbauch E, Dietlein M, et al. Incidence of postradioiodine immunogenic hyperthyroidism/Graves' disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease. Thyroid 2006; 16:281.
  26. Huysmans DA, Buijs WC, van de Ven MT, et al. Dosimetry and risk estimates of radioiodine therapy for large, multinodular goiters. J Nucl Med 1996; 37:2072.
  27. Huysmans DA, Nieuwlaat WA, Erdtsieck RJ, et al. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter. J Clin Endocrinol Metab 2000; 85:3592.
  28. Nieuwlaat WA, Hermus AR, Sivro-Prndelj F, et al. Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. J Clin Endocrinol Metab 2001; 86:5330.
  29. Fast S, Nielsen VE, Grupe P, et al. Optimizing 131I uptake after rhTSH stimulation in patients with nontoxic multinodular goiter: evidence from a prospective, randomized, double-blind study. J Nucl Med 2009; 50:732.
  30. Fast S, Hegedüs L, Grupe P, et al. Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy. J Clin Endocrinol Metab 2010; 95:3719.
  31. Nieuwlaat WA, Huysmans DA, van den Bosch HC, et al. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J Clin Endocrinol Metab 2003; 88:3121.
  32. Bonnema SJ, Hegedüs L. A 30-year perspective on radioiodine therapy of benign nontoxic multinodular goiter. Curr Opin Endocrinol Diabetes Obes 2009; 16:379.
  33. Duntas LH, Cooper DS. Review on the occasion of a decade of recombinant human TSH: prospects and novel uses. Thyroid 2008; 18:509.
  34. Albino CC, Mesa CO Jr, Olandoski M, et al. Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine. J Clin Endocrinol Metab 2005; 90:2775.
  35. Lee YY, Tam KW, Lin YM, et al. Recombinant human thyrotropin before (131)I therapy in patients with nodular goitre: a meta-analysis of randomized controlled trials. Clin Endocrinol (Oxf) 2015; 83:702.
  36. Nielsen VE, Bonnema SJ, Boel-Jørgensen H, et al. Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial. Arch Intern Med 2006; 166:1476.
  37. Bonnema SJ, Nielsen VE, Boel-Jørgensen H, et al. Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial. J Clin Endocrinol Metab 2007; 92:3424.
  38. Fast S, Nielsen VE, Grupe P, et al. Prestimulation with recombinant human thyrotropin (rhTSH) improves the long-term outcome of radioiodine therapy for multinodular nontoxic goiter. J Clin Endocrinol Metab 2012; 97:2653.
  39. Bonnema SJ, Nielsen VE, Boel-Jørgensen H, et al. Recombinant human thyrotropin-stimulated radioiodine therapy of large nodular goiters facilitates tracheal decompression and improves inspiration. J Clin Endocrinol Metab 2008; 93:3981.
  40. Graf H, Fast S, Pacini F, et al. Modified-release recombinant human TSH (MRrhTSH) augments the effect of (131)I therapy in benign multinodular goiter: results from a multicenter international, randomized, placebo-controlled study. J Clin Endocrinol Metab 2011; 96:1368.
  41. Tajiri J. Radioactive iodine therapy for goitrous Hashimoto's thyroiditis. J Clin Endocrinol Metab 2006; 91:4497.
  42. Huang W, Peng C, Huang H, et al. Control of iodine-deficiency disorders following universal salt iodization in Shenzhen, China, 1997-2011. Food Nutr Bull 2013; 34:331.